2023
Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Klaassen F, Chitwood M, Cohen T, Pitzer V, Russi M, Swartwood N, Salomon J, Menzies N. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical Infectious Diseases 2023, 77: 355-361. PMID: 37074868, PMCID: PMC10425195, DOI: 10.1093/cid/ciad210.Peer-Reviewed Original ResearchConceptsSevere diseasePopulation immunityOmicron infectionOmicron variantUS populationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2SARS-CoV-2 Omicron variantRestoration of immunitySyndrome coronavirus 2Bayesian evidence synthesis modelInfection-acquired immunityEvidence synthesis modelSARS-CoV-2Prior immunological exposureCoronavirus 2Additional infectionsImmunological exposureInfectionDiseaseImmunityVaccinationUnited States
2022
Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021
Klaassen F, Chitwood MH, Cohen T, Pitzer VE, Russi M, Swartwood NA, Salomon JA, Menzies NA. Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021. Clinical Infectious Diseases 2022, 76: e350-e359. PMID: 35717642, PMCID: PMC9214178, DOI: 10.1093/cid/ciac438.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionSARS-CoV-2Immunological exposureOmicron variantSevere diseaseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionFuture SARS-CoV-2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantsUS populationSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) vaccinationCoronavirus 2 infectionPopulation-level immunityPrior immunological exposurePopulation immunityImmune escapeVaccination dataInfectionInfection statusVaccinationUS statesEffective protectionDiseaseImmunity
2021
Evaluating the reliability of mobility metrics from aggregated mobile phone data as proxies for SARS-CoV-2 transmission in the USA: a population-based study
Kishore N, Taylor AR, Jacob PE, Vembar N, Cohen T, Buckee CO, Menzies NA. Evaluating the reliability of mobility metrics from aggregated mobile phone data as proxies for SARS-CoV-2 transmission in the USA: a population-based study. The Lancet Digital Health 2021, 4: e27-e36. PMID: 34740555, PMCID: PMC8563007, DOI: 10.1016/s2589-7500(21)00214-4.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 transmissionPopulation-based studyLaboratory-confirmed casesSARS-CoV-2 pandemicSARS-CoV-2Non-pharmaceutical interventionsCOVID-19 transmissionCOVID-19 casesEpidemiological dataReproduction numberEffective reproduction numberHealth StatisticsEquity of accessEpidemic trajectoriesCOVID-19Public healthTransmission indicatorsPopulation levelContact patterns